<DOC>
	<DOC>NCT01488994</DOC>
	<brief_summary>The purpose of this study is to assess BAX 326 pharmacokinetic parameters, to evaluate its hemostatic efficacy, safety, immunogenicity, and changes in health-related quality of life in pediatric patients.</brief_summary>
	<brief_title>BAX 326 Pediatric Study</brief_title>
	<detailed_description>The secondary outcome measure: Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours (h) Post-infusion analysis was not done due to the different time-points for the last PK blood sample, AUC0-72 h was redundant and only total AUC was included in the PK analysis.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Main Participant and/or legal representative has/have voluntarily provided signed informed consent Participant has severe (FIX level &lt; 1%) or moderately severe (FIX level ≤ 2%) hemophilia B Participant is &lt; 12 years old at the time of screening Participant has no evidence of a history of FIX inhibitors (based on the participant's medical records) Participant is immunocompetent as evidenced by a CD4 count ≥ 200 cells/mm^3 Main Participant has a detectable FIX inhibitor at screening, with a titer ≥ 0.6 Bethesda Unit (BU) Participant has a history of allergic reaction, e.g. anaphylaxis, following exposure to FIX concentrate(s) Participant has evidence of an ongoing or recent thrombotic disease Participant has an inherited or acquired hemostatic defect other than hemophilia B</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>